Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI-Reference-Cited by-同舟云学术

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI

Published:2022 Issue:4 Volume:52 Page:304
ISSN:1738-5520
Container-title:Korean Circulation Journal
language:en
Short-container-title:Korean Circ J

Author:

Ki You-Jeong¹^ORCID,Lee Bong Ki²^ORCID,Park Kyung Woo¹^ORCID,Bae Jang-Whan³^ORCID,Hwang Doyeon¹^ORCID,Kang Jeehoon¹^ORCID,Han Jung-Kyu¹^ORCID,Yang Han-Mo¹^ORCID,Kang Hyun-Jae¹^ORCID,Koo Bon-Kwon¹^ORCID,Kim Dong-Bin⁴^ORCID,Chae In-Ho⁵^ORCID,Moon Keon-Woong⁶^ORCID,Park Hyun Woong⁷^ORCID,Won Ki-Bum⁸^ORCID,Jeon Dong Woon⁹^ORCID,Han Kyoo-Rok¹⁰^ORCID,Choi Si Wan¹¹^ORCID,Ryu Jae Kean¹²^ORCID,Jeong Myung Ho¹³^ORCID,Cha Kwang Soo¹⁴^ORCID,Kim Hyo-Soo¹^ORCID,

Affiliation:

1. Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

2. Division of Cardiology, Department of Internal Medicine, Kangwon National University, Chuncheon, Korea.

3. Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.

4. Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, Bucheon, Korea.

5. Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

6. Division of Cardiology, Department of Internal Medicine, St. Vincent’s Hospital, Suwon, Korea.

7. Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.

8. Division of Cardiology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea.

9. Division of Cardiology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.

10. Division of Cardiology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea.

11. Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.

12. Division of Cardiology, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.

13. Division of Cardiology, Department of Internal Medicine, Chonnam University Hospital, Gwangju, Korea.

14. Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.

Publisher

The Korean Society of Cardiology

Subject

Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://e-kcj.org/pdf/10.4070/kcj.2021.0293

Reference24 articles.

1. 2018 ESC/EACTS Guidelines on myocardial revascularization

2. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

3. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

4. Development and Validation of an Ischemic and Bleeding Risk Evaluation Tool in East Asian Patients Receiving Percutaneous Coronary Intervention

5. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients;Experimental and Therapeutic Medicine;2023-09-27

2. Bivalirudin vs heparin in cardiac-cerebral ischemic and bleeding events among Chinese STEMI patients during percutaneous coronary intervention: a retrospective cohort study;Brazilian Journal of Medical and Biological Research;2023

3. The Optimal Duration and De-escalation Strategy of Antiplatelet Agents and Anticoagulation Agents in Korean Patients Undergoing Percutaneous Coronary Intervention;CardioMetabolic Syndrome Journal;2023

4. Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review;Frontiers in Cardiovascular Medicine;2022-10-20

5. Approaches to de-escalation of antiplatelet treatment in stabilized post-myocardial infarction patients with high ischemic risk;Expert Review of Cardiovascular Therapy;2022-10-03